PLUMB PHARMACEUTICALS, INC
- MADISON, WI 53713
- plumbpharma.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 8 days
PLUMB PHARMACEUTICALS, INC’s registration expires on Nov 21, 2026. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About PLUMB PHARMACEUTICALS, INC
- Headquarters
- MADISON, WI 53713
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIHB4LN3AQR226
- CAGE6BVJ1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 3 awards
- Total awarded
- $709,317
- By phase
- SBIR Phase I: 3
- By agency
- Department of Health and Human Services: 2
- National Science Foundation: 1
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2018: 2
- 2014: 1
Awards (most recent first)
A 3-month Release Naltrexone for Addiction Treatment
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $277,749
Sep 1, 2018 – Nov 30, 2019
Solicitation PA18-837 (2018) · Topic NIDA
SBIR Phase I: Refining a 3-month release buprenorphine, advancing a drug delivery platform
SBIR Phase I · National Science Foundation · 2018 · $224,850
Jul 1, 2018 – Dec 31, 2018
Solicitation year 2017 · Topic BM
Long acting injected liposomal buprenorphine for chronic pain/addiction in people
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $206,718
Solicitation DA14-013 (2014) · Topic NIDA · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325412Pharmaceutical Preparation ManufacturingPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
- 9390MISCELLANEOUS FABRICATED NONMETALLIC MATERIALS
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with PLUMB PHARMACEUTICALS, INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.